# Safety and Maintenance of Effect of Ziprasidone Plus a Mood Stabilizer in Bipolar I Disorder (Manic or Mixed)

> **NCT00280566** · PHASE3 · COMPLETED · sponsor: **Pfizer's Upjohn has merged with Mylan to form Viatris Inc.** · enrollment: 584 (actual)

## Conditions studied

- Bipolar Mania
- Bipolar Disorder

## Interventions

- **DRUG:** Placebo
- **DRUG:** Ziprasidone Oral Capsule

## Key facts

- **NCT ID:** NCT00280566
- **Lead sponsor:** Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-12
- **Primary completion:** 2008-05
- **Final completion:** 2008-05
- **Target enrollment:** 584 (ACTUAL)
- **Last updated:** 2021-03-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00280566

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00280566, "Safety and Maintenance of Effect of Ziprasidone Plus a Mood Stabilizer in Bipolar I Disorder (Manic or Mixed)". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00280566. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*